Postdoc (3y) at det Department of Molecular Cell Biology, Institute for Cancer Research

Oslo Universitetssykehus HF - Department of Molecular Cell Biology, Institute fo
Bli kjent med Oslo universitetssykehus

Development of small molecule inhibitor immune therapy

Application deadline: February 15, 2017. Preferred start date: Between February 17-April 1, 2017.


Job description

Immune checkpoint proteins regulate the duration and amplitude of physiological immune responses in normal tissues, which is crucial for self-tolerance and which prevents collateral damage from the immune system. Cancer cells co-opt certain immune-checkpoint pathways as a major mechanism of immune resistance, particularly against T cells that are specific for tumor antigens. We have recently discovered a novel small molecule that inhibits the expression of immune checkpoint proteins on the surface of cancer cells. This project is aimed at optimizing this compound and to explore its commercial potential as novel antiimmune checkpoint cancer therapy.



We are looking for an enthusiastic and determined individual who can work both independently as well as in the context of a team. The successful candidate is capable of conceptual thinking, is looking forward to learning new techniques, has good communication skills and is well organized. Knowledge of basic methods in molecular biology is essential, as well as experience with medicinal chemistry and/or immune checkpoints. Potential candidates have completed (or are close to completing) a PhD degree in biology, with one or several publications in internationally well-regarded, peer-reviewed scientific journals. Applicants with publications in press are also considered.

Interested persons should submit the following documents (note that applications lacking any of these Three requirements will be put aside automatically without further evaluation):

1) A concise application letter explaining your motivation for this position (max 1-2 pages).

2) Curriculum vitae including a list of publications (max 2 pages; CVs that exceed this length will not be considered).

3) Three recent signed reference letters, as well as contact information of these References.

An expert committee will review all applications.

Only applications in Webcruiter will be considered


The Institute for Cancer Research is a high-quality research environment. For information regarding ongoing research at the Institute for Cancer Research and our laboratory see http://ous-research.no/institute/ and http://www.ous-research.no/enserink/.

The position is for three years with potential extension with one year. Questions regarding the position can be directed to Prof. J.M. Enserink (jorrit.enserink@rr-research.no).

Om arbeidsgiveren

Oslo University Hospital is a highly specialized hospital in charge of extensive regional and local hospital assignments. As Scandinavia's largest hospital, we carry out more than 1.2 million patient treatments each year. The hospital has a nationwide responsibility for a number of national and multi-regional assignments, and has several national centers of competence. Oslo University Hospital is responsible for approximately 50 percent of all medical and health care research conducted at Norwegian hospitals, and is a significant role player within the education of a large variety of health care personnel. 

., 0424 Oslo
Forskning, utdanning og vitenskap

Spørsmål om stillingen

Jorrit Enserink
Group leader
Følg firma
3720 følger dette firmaet

., 0424 Oslo


FINN-kode 88988701
Sist endret 13. jan. 2017 15:20

Rapporter annonse